Display Settings:

Format

Send to:

Choose Destination
    Breast Cancer Res. 2005;7(6):255-7. Epub 2005 Nov 11.

    Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.

    Source

    Harvard Medical School, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA. jligibel@partners.org

    Abstract

    Adjuvant hormonal therapy for postmenopausal women with early stage breast cancer has become far more complex over the past several years. This commentary reviews the current status of the five major trials evaluating the use of the aromatase inhibitors in the adjuvant setting. The data currently available suggest that the aromatase inhibitors are efficacious either as upfront therapy or after a course of tamoxifen. Ongoing trials will compare these approaches and guide the use of these agents in the years to come.

    PMID:
    16457700
    [PubMed - indexed for MEDLINE]
    PMCID: PMC1410766
    Free PMC Article

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk